Avacta (LSE:AVCT) is the kind of company that divides opinion. A clinical-stage oncology Business developing a novel way to target cancer drugs, it offers the prospect of transformative science alongside the very real risk of failure. For a company yet to generate meaningful Revenue from its therapies, the debate turns almost entirely on one thing: the clinical evidence.

A precision-oncology platform

Avacta has repositioned itself as a pure-play oncology biopharmaceutical company built around its pre|CISION peptide drug conjugate platform. The idea is elegant: chemotherapy drugs are chemically modified so they only become active inside tumours, where a specific enzyme is present, sparing healthy tissue and reducing side effects. Its lead candidate, AVA6000, a modified form of the chemotherapy doxorubicin, is the clearest test of whether this approach works in patients rather than just in theory.

The evidence so far

AVA6000 has been in a Phase 1b trial, and the company has reported what it describes as highly encouraging efficacy and safety data, including in patients with salivary gland cancer. Importantly, regulators removed a lifetime maximum dose limit after a reassuring cardiac safety profile, a meaningful signal given doxorubicin’s known heart risks. A second candidate, AVA6103, has also entered clinical development. These early results are promising, but Phase 1 data, however encouraging, are not proof of eventual approval.

Why funding shapes the debate

Money is central to the Avacta story. The company held about £16.9 million in cash at the end of 2025 and around £16.4 million by April 2026, having raised roughly £32.5 million over 18 months, with a placing extending its runway into the first quarter of 2027. For a business consuming cash on trials, that runway is finite. Reaching value-creating data before the money runs out, or securing a partner to share the cost, is as important as the science itself.

The evidence that could move the needle

The debate could shift decisively on stronger clinical data. Investors will watch for efficacy in expansion cohorts, confirmation of the favourable cardiac safety profile, and evidence that the pre|CISION mechanism delivers benefit across more than one tumour type. Data expected during 2026 could either validate the platform, potentially attracting partners and funding, or disappoint and deepen scepticism. Because the platform could in principle be applied to many drugs, convincing proof in one setting would have implications well beyond a single cancer.

The risks to weigh

The risks are those of any clinical-stage biotech, and they are substantial. Most drug candidates Fail somewhere between early promise and approval. Avacta is not yet profitable and depends on raising capital, which can dilute existing shareholders. Trials can disappoint, take longer than hoped or reveal safety problems, and even good data must eventually translate into regulatory approval and commercial success. Reliance on a single platform concentrates that risk, and partnering discussions may not conclude on favourable terms.

So what evidence would change the debate?

Convincing, reproducible clinical data is the answer. Clear efficacy across expansion cohorts, a confirmed safety advantage over conventional chemotherapy, and signs the pre|CISION approach works in multiple tumours would strengthen the bull case and could draw in partners to fund later trials. Weak or ambiguous results would do the opposite. For Avacta (LSE:AVCT), the science is genuinely novel and the potential large, but the Investment debate will be settled not by ambition but by the numbers that emerge from its trials. Until those numbers arrive, the shares are likely to remain volatile, swinging on each data release and financing announcement. For patient investors willing to accept binary risk, that Volatility is simply the price of backing genuinely early-stage science with real potential.